Oncology Practice Management Issues

October 2018, Vol 8, No 10

What Does the Future Hold for PBMs? Implications for Oncology Practices

Dawn Holcombe, MBA, FACMPE, ACHE

From the Editor

Pharmacy benefit managers (PBMs) have been seeking greater influence in the oncology market for several years. They are contracted by health plans and employers to manage the drugs covered under pharmacy benefits, which may include newly approved drugs added to the plan; provision of operational controls, such as step edits; prior authorizations; formulary restrictions; and the review of medical necessity for oral medications. [ Read More ]

Tabelecleucel Shows High Response Rates in Patients with EBV-Associated Posttransplant Lymphoma Refractory to Rituximab

Walter Alexander


Patients with Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorders (PTLD) who do not respond to first-line rituximab (Rituxan) therapy are extremely difficult to manage, said Susan E. Prockop, MD, Pediatric Oncologist, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2018 European Hematology Association Congress. [ Read More ]

Opdivo plus Yervoy Approved for MSI-H or dMMR Colorectal Cancer

FDA Approvals, News & Updates

On July 10, 2018, the FDA accelerated the approval of the combination of nivolumab and ipilimumab (Opdivo and Yervoy; Bristol-Myers Squibb) for the treatment of patients aged ≥12 years with metastatic c­o­lorectal cancer (CRC) associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) that progressed after chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan. [ Read More ]

Kisqali Receives Expanded Indications for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

FDA Approvals, News & Updates

On July 18, 2018, the FDA approved 2 new indications for ribociclib (Kisqali; Novartis) for use as (1) initial endocrine-based therapy, in combination with an aromatase inhibitor (AI), for the treatment of pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer; as well as (2) an initial endocrine-based therapy or after disease progression while receiving endocrine-based therapy, in combination with fulvestrant for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. [ Read More ]